These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 31596663)
1. Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens. Mendes RE; Rhomberg PR; Lister T; Cotroneo N; Rubio A; Flamm RK Microb Drug Resist; 2020 Apr; 26(4):319-328. PubMed ID: 31596663 [TBL] [Abstract][Full Text] [Related]
3. Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-non-susceptible Enterobacteriaceae without carbapenemase production. Mutters NT; Zimmermann S; Kaase M; Mischnik A Eur J Clin Microbiol Infect Dis; 2015 Dec; 34(12):2429-37. PubMed ID: 26433746 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986 [TBL] [Abstract][Full Text] [Related]
5. SHV Hyperproduction as a Mechanism for Piperacillin-Tazobactam Resistance in Extended-Spectrum Cephalosporin-Susceptible Han MS; Park KS; Jeon JH; Lee JK; Lee JH; Choi EH; Lee SH Microb Drug Resist; 2020 Apr; 26(4):334-340. PubMed ID: 31651221 [TBL] [Abstract][Full Text] [Related]
6. Potentiation of Antibiotic Activity by a Novel Cationic Peptide: Potency and Spectrum of Activity of SPR741. Corbett D; Wise A; Langley T; Skinner K; Trimby E; Birchall S; Dorali A; Sandiford S; Williams J; Warn P; Vaara M; Lister T Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533232 [TBL] [Abstract][Full Text] [Related]
7. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Aktaş Z; Kayacan C; Oncul O Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508 [TBL] [Abstract][Full Text] [Related]
8. Comparing the activity of broad-spectrum beta-lactams in combination with aminoglycosides against VIM-producing Clark JA; Burgess DS Microbiol Spectr; 2024 Oct; 12(10):e0387623. PubMed ID: 39162554 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China. Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015-2016. Galani I; Souli M; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Antoniadou A; Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1143-1150. PubMed ID: 30825054 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity of temocillin against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains isolated from urinary tract infections in France. Duployez C; Loïez C; Cattoen C; Wallet F; Vachée A Med Mal Infect; 2019 Feb; 49(1):47-53. PubMed ID: 30396720 [TBL] [Abstract][Full Text] [Related]
12. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems]. Kuzucu C; Yetkin F; Görgeç S; Ersoy Y Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015. Sader HS; Castanheira M; Flamm RK Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Titelman E; Iversen A; Kahlmeter G; Giske CG APMIS; 2011 Dec; 119(12):853-63. PubMed ID: 22085361 [TBL] [Abstract][Full Text] [Related]
15. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). Sader HS; Farrell DJ; Flamm RK; Jones RN J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763 [TBL] [Abstract][Full Text] [Related]
16. Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae. Castanheira M; Rhomberg PR; Flamm RK; Jones RN Antimicrob Agents Chemother; 2016 Sep; 60(9):5454-8. PubMed ID: 27381386 [TBL] [Abstract][Full Text] [Related]
17. Activity of temocillin against ESBL-, AmpC-, and/or KPC-producing Enterobacterales isolated in Poland. Kuch A; Zieniuk B; Żabicka D; Van de Velde S; Literacka E; Skoczyńska A; Hryniewicz W Eur J Clin Microbiol Infect Dis; 2020 Jun; 39(6):1185-1191. PubMed ID: 32096107 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755 [TBL] [Abstract][Full Text] [Related]
19. Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae? Bouxom H; Fournier D; Bouiller K; Hocquet D; Bertrand X Int J Antimicrob Agents; 2018 Jul; 52(1):100-103. PubMed ID: 29580930 [TBL] [Abstract][Full Text] [Related]
20. In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli. Tärnberg M; Ostholm-Balkhed A; Monstein HJ; Hällgren A; Hanberger H; Nilsson LE Eur J Clin Microbiol Infect Dis; 2011 Aug; 30(8):981-7. PubMed ID: 21298459 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]